^
Association details:
Biomarker:No biomarker
Cancer:Myelodysplastic Syndrome
Drug:sabatolimab (MBG453) (TIM-3 antagonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes

Published date:
05/25/2021
Excerpt:
Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents.